key: cord-0762337-2v6op6xi authors: Massari, M.; Spila-Alegiani, S.; Morciano, C.; Spuri, M.; Marchione, P.; Felicetti, P.; Belleudi, V.; Poggi, F. R.; Lazzeretti, M.; Ercolanoni, M.; Clagnan, E.; Bovo, E.; Trifiro, G.; Moretti, U.; Monaco, G.; Leone, O.; Da Cas, R.; Petronzelli, F.; Tartaglia, L.; Mores, N.; Zanoni, G.; Rossi, P.; Samez, S.; Zappetti, C.; Marra, A. R.; Menniti-Ippolito, F. title: Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study date: 2022-02-08 journal: nan DOI: 10.1101/2022.02.07.22270020 sha: 0989f570073a20024edbc787b0718469b6032809 doc_id: 762337 cord_uid: 2v6op6xi Objectives To investigate the association between SARS-CoV-2 mRNA vaccines, BNT162b2 and mRNA-1273, and myocarditis/pericarditis. Design Self-Controlled Case Series study (SCCS) using national data on COVID-19 vaccination and emergency care/hospital admissions. Setting Italian Regions (Lombardia, Friuli Venezia Giulia, Veneto, Lazio). Participants 2,861,809 individuals, aged 12-39 years, vaccinated with the first doses of mRNA vaccines (2,405,759 BNT162b2 and 456,050 mRNA-1273) between 27 December 2020 and 30 September 2021. Main outcome measures First diagnosis of myocarditis/pericarditis within the study period. The incidence of events in the exposure risk periods (0-21 days from the vaccination day, subdivided in three equal intervals) for first and second dose was compared with baseline period. The SCCS model was fitted using conditional Poisson regression to estimate Relative Incidences (RI) and Excess of Cases (EC) per 100,000 vaccinated by dose, age, gender and brand. Results During the study period, 441 participants aged 12-39 years developed myocarditis/pericarditis (346 BNT162b2 and 95 mRNA-1273). During the 21-day risk interval there were 114 cases of myocarditis/pericarditis (74 BNT162b2 and 40 mRNA-1273) corresponding to a RI of 1.27 (0.87-1.85) and 2.16 (1.50-3.10) after first and second dose, respectively. An increased risk of myocarditis/pericarditis at (0-7) days was observed after first [RI=6.55; 95% Confidence Interval (2.73-15.72); EC per 100,000 vaccinated=2.0 (1.5-2.3)] and second dose [RI=7.59 (3.26-17.65); EC=5.5 (4.4-5.9)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.39 (2.02-5.68); EC=0.8 (0.6-1.0)]. In males, an increased risk at (0-7) days was observed after first [RI=12.28, 4.09-36.83; EC=3.8 (3.1-4.0)] and second dose [RI=11.91 (3.88-36.53); EC=8.8 (7.2-9.4)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.45 (1.78-6.68); EC=1.0 (0.6-1.2)]. In females, an increased risk at (0-7) days was observed after second dose of BNT162b2 [RI=3.38 (1.47-7.74); EC=0.7 (0.3-0.9)]. At (0-7) days an increased risk following second dose of BNT162b2 was observed in the 12-17 years old [RI=5.74, (1.52-21.72); EC=1.7 (0.7-1.9)] and in 18-29 years old [RI=4.02 (1.81-8.91); EC=1.1 (0.6-1.3)]. At (0-7) days an increased risk after first [RI=7.58 (2.62-21.94); EC=3.5 (2.4-3.8)] and second [RI=9.58 (3.32-27.58); EC=8.3 (6.7-9.2)] dose of mRNA-1273 was found in 18-29 years old and after first dose in 30-39 years old [RI=6.57 (1.32-32.63); EC=1.0 (0.3-1.1)]. Conclusions This population-based study indicates that mRNA vaccines were associated with myocarditis/pericarditis in the population younger than 40 years, whereas no association was observed in older subjects. The risk increased after the second dose and in the youngest for both vaccines, remained moderate following vaccination with BNT162b2, while was higher in males following vaccination with mRNA-1273. The public health implication of these findings should be weighed in the light of the overall efficacy and safety profile of both vaccines. Intensive post-marketing surveillance of SARS-CoV-2 vaccines is ongoing worldwide to provide updated information on their effectiveness and safety, thereby supporting regulatory benefit/risk assessment. Since early phase of the global vaccination campaign, case series 1-3 and pharmacovigilance reports 4,5 on myocarditis and pericarditis following the COVID-19 mRNA vaccine administration were published. Both events were included as related to COVID-19 disease in the early and updated Priority List of COVID-19 Adverse events of special interest, developed by Brighton Collaboration Group and Safety Platform for Emergency vACcines (SPEAC), in order to harmonize safety assessment of COVID-19 vaccines in pre-and post-marketing setting. 6 Moreover, as per core requirements for Risk Management Plan (RMP), they have been periodically monitored through routine pharmacovigilance activities in the Monthly Summary Safety Reports of all COVID-19 vaccines. 7 On July 2021, the COVID-19 subcommittee of WHO Global Advisory Committee on Vaccine Safety reported that very rare cases of myocarditis and pericarditis had occurred more often in adolescents or young adults and after the second dose, especially within a few days after COVID-19 mRNA vaccines, and encouraged countries to strengthen the monitoring of myocarditis/pericarditis. 8 At the same time, EMA's Pharmacovigilance Risk Assessment Committee (PRAC) began an assessment on signals of myocarditis and pericarditis with Pfizer mRNA vaccine (BNT162b2) and Moderna mRNA vaccine (mRNA-1273) and concluded that both cardiac conditions can occur in very rare cases following vaccination with the COVID-19 mRNA vaccines. Thus, the Committee recommended to update the product information and the RMP for these vaccines, together with a direct healthcare professional communication to raise awareness among healthcare professionals. 9 In October 2021, further data were available from an unpublished Nordic population-based register study on myocarditis and pericarditis in northern Europe, that prompted some public health organisations in the Nordic countries (e.g. Sweden, Finland, Norway, Iceland) 10 either to pause the use of the mRNA-1273 or to recommend the use of the BNT162b2 rather than mRNA-1273 in younger people and/or younger males. In December 2021, the PRAC re-assessed the relevant safety signal, based on the Nordic study and on a study conducted using data from the French national health system (Epi-phare), 11 concluding that the risk for both events is overall "very rare" (up to one in 10,000 vaccinated people) and greater in younger males. A further update of product information was recommended, while the benefit/risk was confirmed as positive for the whole indication. 12 In line with these findings, recent published data from large population-based studies from Israel, US, UK and Denmark documented that the risks of myocarditis/pericarditis following mRNA vaccines differ by age groups, gender, and vaccine brand, with an higher risk in those younger than 40 years. [13] [14] [15] [16] [17] [18] In Italy, SARS-CoV-2 vaccines have been administered since late December 2020 and have been offered to the population according to a priority scheme, considering profession, age and health condition. Vaccination in adolescent (≥12 years) started on 31 May and 28 July 2021 for BNT162b2 and mRNA-1273, respectively. Along with the enhanced passive surveillance of the Italian PharmacoVigilance network, an active surveillance, based on Regional health care claims databases, was set up by the Italian National Institute of Health (ISS) and the Italian Medicines Agency (AIFA) to provide real-world data on SARS-CoV-2 vaccine safety. In this paper, we present results of the first population based Italian study investigating the association between mRNA based COVID-19 vaccines (BNT162b2 and mRNA-1273) and 4/21 myocarditis/pericarditis in the population of vaccinated persons aged 12-39 years, during the period 27 December 2020 and 30 September 2021. The active surveillance is based on a dynamic multi-regional observational cohort. A distributed analysis framework is applied using TheShinISS, an R-based open-source statistical tool, developed by the National Institute of Health, 19 that locally processes data collected and updated every four months from regional health care databases according to ad hoc, study-tailored, common data model. Data on vaccination exposure, on hospitalization for myocarditis/pericarditis and on covariates were retrieved from several routinely collected regional healthcare claims databases: -COVID-19 vaccination registry to identify information on administered vaccines (brand, date of administration and doses for all vaccinated subjects); -population registry to identify information an age, gender and vital status; causes of death are not recorded in this registry; -hospital discharge and emergency care visit databases to identify myocarditis/pericarditis events (pre and post vaccination) and information on a predefined list of potential confounders in the period preceding the vaccination; -pharmacy claims and copayment exemptions databases to obtain information on potential confounders in the period preceding the vaccination; -vaccination registry to identify other vaccinations (e.g. flu and pneumococcal vaccines) administered in the period pre-and post-COVID-19 vaccination; -COVID-19 surveillance system to obtain information on Sars-Cov2 infection data and related outcomes. We used a Self-Controlled Case Series (SCCS) design. [20] [21] [22] [23] [24] The SCCS design has emerged as a key methodology for studying the safety of vaccines and medicines. This approach only requires information from individuals who have experienced the event of interest, and automatically controls for multiplicative time-invariant confounders, even when these are unmeasured or unknown. Originally designed to analyze the association between vaccination and specific events under the key assumption that events do not influence post-event exposures, this method has been adapted to event dependent exposures, for example when occurrence of an event may preclude any subsequent exposure (SCCS method for censored, perturbed or curtailed post-event exposures). [23] [24] [25] This is the case in observational studies of vaccines when the event of interest could be a contraindication to vaccination. By using the adapted SCCS method for event dependent exposures, we estimated the relative incidence of myocarditis/pericarditis following pre-specified windows at risk after vaccination, in a within-person comparison of different time-periods. The method allows for the control of all time-independent characteristics of subjects. The SCCS method allows also for adjustment of potential time-varying confounders such as seasonal variation in risks. We investigated the association between mRNA based COVID-19 vaccines and subsequent onset of myocarditis/pericarditis in the population aged 12-39 years in the period 27 December 2020 -30 September 2021 (the latest date for which outcome data were available). Regional claims data were locally transformed into a study-specific Common Data Model and locally processed using TheShinISS. In the end, regional pseudonymized datasets were provided to the National Institute of Health for centralized analysis, in compliance with EU General Data Protection Regulation. Over the last two years, TheShinISS framework has been employed in several large scale observational studies exploring the association between several exposures and COVID-19 onset/prognosis as well as other drug and vaccinerelated research topics and is currently maintained by a collaborative research network. 19, [26] [27] [28] The relational scheme of the study databases as well as TheShinISS elaborating process is described in Supplementary Figure 1 . Four Italian Regions (Lombardia, Veneto, Friuli Venezia Giulia, and Lazio), representing 36% of the population aged 12-39 years, contributed data of all vaccinated persons in this age group, in a period ranging from 27/12/2020 to the latest date for which data on outcomes were available, which varied across Regions: Lombardia up to 30/09/2021, Veneto up to 20/06/2021, Friuli Venezia Giulia up to 31/08/2021, and Lazio up to 16/06/2021). We included in the study all the persons aged 12-39 years who received a first dose of mRNA vaccines and were admitted to emergency care or hospital with the outcomes of interest. We excluded individuals with missing age and sex, or without information on vaccine brand at the first and/or second dose. Furthermore, we excluded individuals with a history of myocarditis or pericarditis within 365 days leading up to the start of the study period. The observation period for each case ranged from 27 December 2020 to the end of follow-up, which occurs at the time of death or at the end of Region-specific study period, whichever comes first. The The exposures of interest were the first or second dose of BNT162b2 and mRNA-1273 vaccines. The exposure risk period was defined as [0-21) days after first or second dose administration (vaccination date), which included day 0, the day of vaccination. This risk period was further subdivided into prespecified time-periods: [0-7), [7] [8] [9] [10] [11] [12] [13] [14] , and [14] [15] [16] [17] [18] [19] [20] [21] after each exposure date. The unexposed baseline period (reference period) was defined as any time of observation out of the risk periods. 6/21 after occurrence of an event. 20, 24 Five 45-day calendar periods were considered as time-varying covariate controlling for the seasonal effect. We also estimated the Excess of Cases (EC) per 100,000 vaccinated. 29 We carried out subgroup analyses by age group (12-17, 18-29, 30-39 years) , gender and vaccine brand (BNT162b2 and mRNA-1273). To assess the robustness of the primary analysis, the following sensitivity analyses were conducted: a) event-dependent exposures handling -in addition to the SCCS adjusted for event dependent exposures, we used the SCSS standard starting the observation time at the first and second dose, respectively; b) observation/exposure time period -we restricted the analysis to the study period from 27 December 2020 to 31 May 2021 20, 30 and to the study period from 1 June 2021 to 30 September 2021; we repeated the primary analysis excluding day 0 from the [0-7) day risk interval; c) heterologous vaccination -we carried out the primary analysis excluding individuals who received two different vaccine brands at the first and second dose or censoring individuals who received a different vaccine brand at the second dose (in the primary analysis the second dose was assumed to be of the same brand as the first one); d) SARS-CoV-2 infection -we restricted the analyses to subjects without a SARS-CoV-2 positive test before the occurrence of the event (any time) and within 10 days after the event. We conducted also an ancillary analysis reproducing the primary SCCS analysis in the vaccinated persons aged over 40 years. The analyses were performed using R version 4. following a second dose of the BNT162b2 and mRNA-1273, we estimated an additional 0.8 (95% CI 0.6-1.0) and 5.5 (95% CI 4.4-5.9) myocarditis/pericarditis cases per 100,000 vaccinated, respectively. Table 4 and Figure 2 show the Relative Incidences and EC in the [0-7) day risk period by age and gender (Supplementary Tables 2-11 , Supplementary Figure 2 ). In males, the risk of myocarditis/pericarditis increased in the [0-7) days following a first dose of mRNA-1273 (RI=12.28; 95% CI 4.09-36.83), and following a second dose of BNT162b2 (RI=3.45; 95% CI 1.78-6.68) and mRNA-1273 (RI=11.91; 95% CI 3.88-36.53). In females, we found an increased risk of myocarditis/pericarditis [0-7) days following a second dose of BNT162b2 (RI=3.38; 95% CI 1.47-7.74), while no association was observed with mRNA-1273. In males, we estimated an additional 3.8 (95% CI 3.1-4.0) EC per 100,000 in the [0-7) days following a first dose of mRNA-1273, and an additional 1.0 (95% CI 0.6-1.2) and 8.8 (95% CI 7.2-9.4) EC per 100,000 in the [0-7) days following a second dose of BNT162b2 and mRNA-1273, respectively. In females, we estimated an additional 0.7 (95% CI 0.3-0.9) EC per 100,000 in the [0-7) days following a second dose of BNT162b2. Analyzing data by age group, we estimated an increased risk of myocarditis/pericarditis [0-7) days following the second dose of BNT162b2 (RI=5.74; 95% CI 1.52-21.72) in those aged 12-17 years. Number of events were insufficient to estimate associations with mRNA-1273. There were, however, three events in the [0-7) day interval compared to one event in the remaining risk intervals after the second dose. In the 18-29 year age group, we observed an increased risk of myocarditis/pericarditis [0-7) days following a first and second dose of mRNA-1273, respectively (RI=7.58; 95% CI 2.62-21.94) and (RI=9.58; 95% CI 3.32-27.58), and following the second dose of BNT162b2 (RI=4.02; 95% CI 1.81-8.91). In the age group 30-39 years, we found an increased risk of myocarditis/pericarditis [0-7) days (RI=6.57; 95% CI 1.32-32.63) and [7] [8] [9] [10] [11] [12] [13] [14] days (RI=5.87; 95% CI 1.34-25.74) following the first doses of mRNA-1273, while no association was observed with BNT162b2. In the age group 12-17 years, we estimated an additional 1.7 (95% CI 0.7-1.9) EC per 100,000 in the [0-7) days following a second dose of BNT162b2. In the age group 18-29 years, we estimated an additional 3.5 (95% CI 2.4-3.8) EC per 100,000 in the [0-7) days following a first dose of mRNA-1273; an additional 1.1 (95% CI 0.6-1.3) and 8.3 (95% CI 6.7-9.2) EC per 100,000 in the [0-7) days following a second dose of BNT162b2 and mRNA-1273, respectively. In the age group 30-39 years, we estimated an additional 1.0 (95% CI 0.3-1.1) EC per 100,000 both in the [0-7) days and [7] [8] [9] [10] [11] [12] [13] [14] days following the first dose of mRNA-1273, respectively. All sensitivity analyses were consistent with the main results of the study (Supplementary Table 12 ). The sensitivity analysis that was conducted to highlight the potential effect of notoriety bias (by restricting the observation period before and after 31 May 2021) indicated that RIs estimates and confidence intervals are largely overlapping, even though we cannot rule out a slight inflation of the estimates in the second period. Table 13 ). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in This first Italian large population-based study covering about 3 million of vaccinated persons aged 12-39 years in Italy found an association between myocarditis/pericarditis within a week following each dose of mRNA vaccines. The risk of myocarditis/pericarditis is particularly higher after seven days following the first or second dose of mRNA-1273 vaccine in the overall population. Subgroup analysis by gender suggested that the increased risk was present only in males after both the first and second dose with 3.8 and 8.8 EC per 100,000 vaccinated, respectively. Stratifying by age, greater risks were found in those aged 18-29 years with EC of 3.5 and 8.3 per 100,000 following the first and the second doses, respectively. In the age group 12-17 years, the number of events were insufficient for risk estimate. We also observed an association between BNT162b2 and myocarditis/pericarditis, but only in the seven days following the second dose, where the risks remain similar between males and females with 1.0 and 0.7 EC per 100,000 vaccinated, respectively. In the age groups 12-17 years and 18-29 years, where the increased risks were confined, the estimated EC were 1.7 and 1.1 per 100,000 vaccinated, respectively. Vaccine-associated acute myocarditis is generally attributable to allergic/hypersensitivity reactions as observed in other vaccines. 32 However, the pathophysiology of myocarditis and pericarditis associated to mRNA vaccines is not clearly understood and different mechanisms have been postulated. Molecular mimicry between the spike protein and self-antigens, 33 trigger of preexisting dysregulated immune pathways, immune response to mRNA 34 or dysregulated cytokine expression 35 have been proposed. Our results on the increased risk in the seven days after each dose are consistent with the onset of viral myocarditis symptoms often reported in the first week from the infection. 32, 36 Moreover, it has been postulated that a very high antibody response to mRNA vaccines in predisposed young people may elicit an uncontrolled inflammatory response similar to multisystem inflammatory syndrome observed in children (MIS-C) with SARS-CoV-2 infection. 37 To date, no clear evidence is available and further studies are needed to clarify which is the exact mechanism of mRNA vaccines-related myocarditis and pericarditis. Furthermore, our observation on the increased risk in young males resembles classical epidemiological features of myocarditis due to other causes, 38 included COVID-19 related myocarditis, 39 but the exact role of age and sex is still unclear. In a recent review, a possible effect of sex hormones in immune response is summarized, with a possible role of testosterone by a combined mechanism of inhibition of antiinflammatory cells and commitment to a Th1-type immune response in male and of inhibitory effects of estrogen on proinflammatory T cells in female. 40 In line with a previous US study 15 we identified an association between mRNA vaccines and myocarditis/pericarditis in individuals younger than 40 years within the 0-7 day period following the first and the second doses. Our results are also consistent with observational studies which documented markedly increased risk of myocarditis in England, 16 and myocarditis or myopericarditis in Denmark 18 in the population vaccinated with mRNA-1273. Specifically, in the Danish study it was reported a strong association between mRNA-1273 and myocarditis or myopericarditis within 28 days from vaccination (Hazard Ratio, HR=5.24; 95% CI 2.47-11.12) with an estimated of 57 EC per 1,000,000 vaccinated. The UK study also suggested a strong All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270020 doi: medRxiv preprint 9/21 association within the 1-28 days after first and second mRNA-1273 dose (IRR=3.89; 95% CI 1.60-9.44; and 20.71, 95% CI 4.02-106.68; respectively) corresponding to 8 and 15 EC per 1,000,000 vaccinated. 16 A recent updated self-controlled case series analysis of English data, stratified by age and gender, also reported an higher risk in male aged less than 40 years (first dose Incidence Rate Ratio, IRR=2.34; 95% CI 1.03-5.34; second dose IRR=16.52; 95% CI 9.10-30.00) corresponding to EC of 12 and 101 per 1,000,000 respectively; a markedly increased risk was also observed in females after the second dose of mRNA-1273 (IRR=7.55; 95% CI 1.67-34.12) with 8 EC of per 1,000,000 vaccinated. 17 Results on the association between BNT162b2 and myocarditis/pericarditis are less conclusive. We found an association in the seven days after the second dose both in males and females. Findings from Israel 14 and England 17 confirmed an association in adolescent and adult males younger than 40 years, but not in female participants. Particularly, the English study, including data on the third dose of BNT162b2, highlighted that in males 12-39 years the risk sequentially increased following each dose of vaccine (IRR=1.66, 3.41 and 7.60, respectively) with an EC of 3, 12 and 13 per 1,000,000 vaccinated, respectively. No association was found in females and in males older than 40 years. 17 Conversely, a population-based study conducted in Denmark 18 , with a more stringent case definition, did not support the association between BNT162b2 and myocarditis or myopericarditis in the 28 days after vaccination, both overall and in the 12-39 year group, but an association only in females (HR=3.73; 95% CI 1.82-7.65) was found. Our study strengths include the large sample size, the broad geographical distribution of the cohort and the availability of data on SARS-CoV-2 diagnosis and outcomes, comorbidities and patients' demographic characteristics from health care databases. The large sample size (about 3 million vaccinated people aged 12-39 years) allowed to look at fine risk intervals following vaccinations and carrying several subgroup analyses. Since data were collected from routinely collected data in the claims databases, irrespective of research question, there is no potential for recall or selection bias. Another methodological strength of our study is the choice of the SCCS method modified to handle event-dependent exposures. This method properly controls for the estimate inflation occurring when vaccination is markedly delayed or cancelled (i.e. myocarditis/pericarditis is a contraindication of vaccination). Conversely, the standard SCCS method adapted by including a pre-vaccination risk period is a strategy working for short term delays. 21, 23, 24 However, our study also has limitations. First, there is the possibility of notoriety bias due to overdiagnosis of cases of myocarditis/pericarditis because of the increased public and medical awareness of these potential adverse events following mRNA vaccination. Such bias is probably minimal and the effect observed in the sensitivity analysis could be partly explained by a different age profile and characteristics of the two vaccinated population before and after 31 May 2021. Second, diagnoses of myocarditis and pericarditis were retrieved from hospital discharge and emergency care visit databases, and they were not validated through the review of clinical records. For this reason, a misclassification of the outcomes that biased the association cannot be excluded. However, an over or under-representation of the ascertainment of the outcomes is unlikely, since we relied on the settings from which codes were derived i.e. emergency care and hospital care where the available facilities made it possible an accurate diagnosis, that it is known cannot be based only on clinical assessment. Third, we did not collect further information to assess the severity of the outcomes. To date, data were collected without differentiating between emergency care admission and hospital admission and length of the hospitalization was not available. Lastly, although the large sample size including about three million of vaccinated persons, due All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in to the small number of events, it was not possible to provide robust model estimates in some subgroup analyses (i.e. mRNA-1273 in the subgroup of adolescents aged 12-17 years). This population-based study indicates that mRNA vaccines were associated with myocarditis/pericarditis in the population younger than 40 years, whereas no association was observed in older subjects. According to our results the risk increased after the second dose and in the youngest for both vaccines, remained moderate following vaccination with BNT162b2, while was higher in males following vaccination with mRNA-1273. However, vaccine-associated risks should always be evaluated in the light of their efficacy in preventing serious COVID-19 disease and death. Further monitoring of data from this active surveillance is needed to evaluate the relationship between mRNA vaccines and myocarditis/pericarditis by age within gender, including population of children (5-11 years old) and the effect of third dose (booster dose). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in This study was approved by the National Unique Ethics Committee for the evaluation of clinical trials of medicines for human use and medical devices for patients with COVID-19 of the National Institute for Infectious Diseases "Lazzaro Spallanzani" in Rome (n. 335, 17/05/2021 and n. 399, 02/09/2021). Due to regional and national data privacy regulations, individual-level data cannot be shared openly. Aggregated or jittered data will be shared on reasonable request to the corresponding author (CM). The lead authors (the manuscript's guarantors) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. The study coordinators will continue to update the analyses based on these data sources. The study findings will also be disseminated by ISS, AIFA and Regional institutions web sites. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270020 doi: medRxiv preprint Ari Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19 Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) Platform for Emergency vACcines. SO2-D2.1.2 Priority List of COVID-19 Adverse events of special interest: Quarterly update EMA/PRAC/234052/2021. Consideration on core requirements for RMPs of COVID19 vaccines. coreRMP19 guidance v2.0. 10 COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines 9 Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis Covid-19: Sweden, Norway, and Finland suspend use of Moderna vaccine in young people "as a precaution Myocardite et péricardite après la vaccination Covid-19 EMA/PRAC/683817/2021. PRAC recommendations on signals. Adopted at the Safety of the BNT162b2 mRNA Covid-34432976 19 vaccine in a nationwide setting Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex Surveillance for adverse events after COVID-19 mRNA vaccination Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection Risk of myocarditis following sequential COVID-19 vaccinations by age and sex SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study TheShinISS: an open-source tool for conducting distributed analyses within pharmacoepidemiological multi-database studies Tutorial in bio-statistics: the self-controlled case series method Self controlled case series methods: an alternative to standard epidemiological study designs Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice Case series analysis for censored, perturbed, or curtailed post-event exposures Self-Controlled Case Series Studies. A Modelling Guide with R Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID19: A Retrospective Italian Cohort Study of 43,000 Patients Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project Immunosuppressive therapy after solid organ transplantation in Italy: a pilot study of the CESIT* project. XI Congresso Nazionale SISMEC Drug safety studies and measures of effect using the self-controlled case series design COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines GACVS 26 SCCS: The Self-Controlled Case Series Method. R. package version 1.5 Myocarditis and pericarditis after immunization: gaining insights through the vaccine adverse event reporting system Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? COVID-19 Myocarditis: Quantitative analysis of the inflammatory infiltrate and a proposed mechanism A Prospective Study of the Incidence of myocarditis/Pericarditis and New Onset Cardiac Symptoms following Smallpox and Influenza Vaccination Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy COVID-19 and cardiovascular disease Myocarditis With COVID-19 mRNA Vaccines yrs: years; *Considering the small number of cases in the vaccinated with mRNA-1273 of age 12-17 years, it was not possible to provide any estimate Excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-7) day risk interval post vaccination